



**DSPACE**

<https://dspace.org/>

**An audit of clinically triaged women at low risk for breast cancer presenting to the Helen Joseph Mammography Unit, Johannesburg**

**Naidu, Lavandhra R.**

**2024**

<https://hdl.handle.net/10539/37854>



An Audit of Clinically Triaged Women at Low Risk for Breast Cancer Presenting to the  
Helen Joseph Mammography Unit, Johannesburg

Dr Lavandhra R Naidu

A research report submitted in format of a submissible article to the Faculty of Health  
Sciences, University of the Witwatersrand, Johannesburg, in partial fulfilment of the  
requirements for the degree of Master of Medicine in Diagnostic Radiology

Johannesburg, 21<sup>st</sup> May 2022

## Declaration

I, Lavandhra Rajendran Naidu, declare that this research report is my own work. It is being submitted for the degree of MMed (Diagnostic Radiology) at the University of the Witwatersrand, Johannesburg. It has not been submitted before for any degree or examination at this or any other University.

Dr LR Naidu

On this 21<sup>st</sup> Day of May 2022

## Publications and presentations

This article has been submitted and accepted for publication in the June 2022 edition of the South African Journal of Surgery.

It has never been presented at a congress.

Funding: No external funding was required for the purpose of this study.

Research Ethics Committee Approval: Ethics clearance certificate was obtained from The University of the Witwatersrand, Johannesburg. Ethics number: M201025, Appendix A.

Declaration of Conflict of Interest: The author declares no conflict of interest.

## **Abstract**

### **BACKGROUND**

The Helen Joseph Hospital (HJH) Breast Clinic utilises a clinical triage system to stratify patients based on their risk of breast cancer into high, medium, or low risk profiles. This allows for timeous imaging and subsequent management of those patients at increased risk for breast cancer.

### **OBJECTIVES**

The primary objective was to determine the cancer detection rate (CDR). The secondary objective was to correlate biopsy results with the Breast Imaging – Reporting and Data System (BI-RADS) risk-assessment.

### **METHODS**

A retrospective audit of the patients at low risk for breast cancer who were referred to the Breast Imaging Unit (BIU) in 2019 at HJH. Patients were clinically assessed as low risk based on a triage form (Figure 4) and were identified using the imaging files stored in the BIU. Results were recorded on Microsoft Excel and calculated as per the American College of Radiology guidelines.

### **RESULTS**

The total population sample consisted of 398 patients. Two patients were characterised as BI-RADS 4 and underwent breast biopsies. One patient was diagnosed with histologically proven breast cancer.

The CDR was 2.51% and the most representative age group was the 60 to 69 years one. The most common BI-RADS breast density assessment was group B while the most common BI-RADS risk assessment was category 2.

### **CONCLUSION**

Amongst the low-risk population, both the CDR and spectrum of disease was comparable that of a screening population. This may be due to the use of a triage system prior to imaging, as well as an increase in clinical awareness of breast cancer within a tertiary institution.

## Table of Contents

|                                                       |             |
|-------------------------------------------------------|-------------|
| <b>Declaration.....</b>                               | <b>iii</b>  |
| <b>Publications and presentations .....</b>           | <b>iv</b>   |
| <b>Abstract.....</b>                                  | <b>viii</b> |
| <b>A. List of Figures.....</b>                        | <b>x</b>    |
| <b>B. List of Tables .....</b>                        | <b>xi</b>   |
| <b>C. List of Abbreviations and Terminology .....</b> | <b>xii</b>  |
| <b>1 Rationale .....</b>                              | <b>1</b>    |
| <b>2 Introduction.....</b>                            | <b>1</b>    |
| 2.1 Epidemiology of Breast Cancer .....               | 1           |
| 2.2 Screening Mammography .....                       | 1           |
| 2.2.1 Southern African Recommendations .....          | 2           |
| 2.2.2 Rationale of Screening Mammography .....        | 2           |
| <b>3 Primary Objective.....</b>                       | <b>3</b>    |
| <b>4 Secondary Objectives .....</b>                   | <b>3</b>    |
| <b>5 Methodology .....</b>                            | <b>3</b>    |
| 5.1 Research Paradigm.....                            | 3           |
| 5.2 Sample .....                                      | 3           |
| 5.2.1 Inclusion Criteria .....                        | 3           |
| 5.2.2 Exclusion Criteria .....                        | 3           |
| 5.3 Time Period .....                                 | 7           |
| 5.4 Materials and Methods .....                       | 7           |
| 5.5 Data Collection .....                             | 7           |
| <b>6 Data Analysis and Statistics .....</b>           | <b>8</b>    |
| <b>7 Ethics.....</b>                                  | <b>8</b>    |
| <b>8 Results .....</b>                                | <b>9</b>    |
| 8.1 Figures and Tables .....                          | 9           |
| 8.2 Calculations.....                                 | 15          |
| <b>9 Discussion.....</b>                              | <b>16</b>   |
| <b>10 Study Limitations.....</b>                      | <b>18</b>   |
| <b>11 Conclusion .....</b>                            | <b>18</b>   |
| <b>12 Bibliography .....</b>                          | <b>19</b>   |
| <b>13 Appendix.....</b>                               | <b>21</b>   |

## **A. List of Figures**

|                                                                   |           |
|-------------------------------------------------------------------|-----------|
| <b>Figure 1: The HJH Breast Clinic Triage Form.....</b>           | <b>5</b>  |
| <b>Figure 2: Age group versus patient count.....</b>              | <b>9</b>  |
| <b>Figure 3: Patient Age versus BI-RADS Risk Assessment .....</b> | <b>10</b> |
| <b>Figure 4: Patient age versus BI-RADS breast density.....</b>   | <b>11</b> |
| <b>Figure 5: Summarised findings versus total count .....</b>     | <b>16</b> |

## **B. List of Tables**

|                                                                    |           |
|--------------------------------------------------------------------|-----------|
| <b>Table 1:Triage criteria .....</b>                               | <b>6</b>  |
| <b>Table 2: BI-RADS Classification .....</b>                       | <b>8</b>  |
| <b>Table 3: BIRADS Risk Assessment .....</b>                       | <b>9</b>  |
| <b>Table 4: BIRADS Breast Density .....</b>                        | <b>11</b> |
| <b>Table 5: Features of Mammographically Detected Masses .....</b> | <b>12</b> |
| <b>Table 6: Features of Sonographically Detected Masses .....</b>  | <b>13</b> |
| <b>Table 7: Other Sonographic Findings.....</b>                    | <b>13</b> |
| <b>Table 8: Calcifications .....</b>                               | <b>14</b> |
| <b>Table 9: Characteristics of Masses That Were Biopsied.....</b>  | <b>14</b> |
| <b>Table 10: Confusion Matrix.....</b>                             | <b>15</b> |

### **C. List of Abbreviations and Terminology**

|          |                                             |
|----------|---------------------------------------------|
| ACR      | American College of Radiology               |
| BCSC     | Breast Cancer Screening Consortium          |
| BIU      | Breast Imaging Unit                         |
| BI-RADS  | Breast Imaging – Reporting and Data System  |
| CDR      | Cancer Detection Rate                       |
| HJH      | Helen Joseph Hospital                       |
| GLOBOCAN | Global Cancer Observatory                   |
| CANSA    | The Cancer Association of South Africa      |
| RSSA     | The Radiological Society of South Africa    |
| BISSA    | The Breast Imaging Society of South African |
| USPTF    | United States Preventative Task Force       |
| MMG      | Mammogram                                   |
| USS      | Ultrasound                                  |
| NA       | Not applicable                              |

## **1 Rationale**

Helen Joseph Hospital (HJH) is a tertiary-level hospital, within Johannesburg, South Africa, which offers an open access breast clinic to members of the public. Patients who are concerned about breast pathology of either benign or malignant origin present to the breast clinic where they are colour triaged into green (low risk), yellow (medium risk) or red cases (high risk). This reflects their overall risk for breast cancer. Low risk females are defined as individuals over the age of 40 who present with bilateral typical breast pain from no other medical cause or those who are asymptomatic and present for breast evaluation.

The purpose of this study was to conduct a retrospective audit of the HJH Breast Imaging Unit (BIU), to describe the spectrum of disease and the radiological findings within a low-risk triage group, and to correlate this with the histology when appropriate.

## **2 Introduction**

### **2.1 Epidemiology of Breast Cancer**

A global increase in population, compounded by an increase in life-expectancy and westernization of lifestyle has seen an increase in cancer as a major cause of morbidity and mortality.<sup>(1)</sup> Breast cancer remains the foremost cancer in females in both high and middle-to-low income countries.<sup>(2)</sup> In 2018 it accounted for 11.6% of all newly diagnosed cancers and 6.6% of all cancer-related mortalities globally.<sup>(2)</sup> Predictions estimate that it will reach up to 22 million new cases within the next two decades.<sup>(3)</sup> According to GLOBOCAN 2018, the incidence of breast cancer is highest in the first world, but its mortality is greatest in a third world setting.<sup>(4)</sup> The pooled crude incidence of breast cancer was 24.5 per 100 000 person years across the African continent.<sup>(5)</sup> The 2018 Ekurhuleni Population Based Cancer Registry demonstrated that breast cancer was the most common cancer amongst the female population within this Johannesburg district.<sup>(6)</sup>

### **2.2 Screening Mammography**

Breast screening is the process whereby radiological imaging is utilised within a population of asymptomatic patients. The primary aim is to improve the detection of breast cancer.<sup>(7)</sup> Mammography is the only screening tool proven to decrease

mortality and as such, it remains the gold standard and the corner stone of all screening programs.<sup>(8)</sup>

#### 2.2.1 Southern African Recommendations

South Africa does not have a formalised national screening programme.<sup>(9)</sup>

Multiple institutions have different recommendations.

Cancer Association of South Africa (CANSa) recommends annual screening mammogram for all females over the age of 40 who are asymptomatic.<sup>(10)</sup>

The Radiological Society of South Africa (RSSA) and The Breast Imaging Society of South African (BISSA) both advise self-care examination in combination with annual screening between ages 40-70.<sup>(9)</sup>

#### 2.2.2 Rationale of Screening Mammography

There is much debate as to the role that breast screening plays in reducing the overall mortality rate.<sup>(11)</sup> Individuals who attended screening programs have a 41% decrease in their 10-year breast cancer mortality rate as well as a 25% decrease in the incidence of advanced breast cancer.<sup>(12)</sup>

The Canadian National Breast Screening Study follow up published in 2014 demonstrated that in females aged 40-59, annual mammography is equivalent to that of a physical examination in decreasing breast cancer mortality.<sup>(13)</sup> It stated that there was no statistical difference in the mortality of patients who underwent screening versus those that did not and that the screening group was at increased risk of over-diagnosing cancer.<sup>(13)</sup>

The United States Preventative Services Task Force (USPSTF) has recommended that screening begin from the age of 50, biennial, in order to reduce the rate of over-diagnosis.<sup>(14)</sup> The National Health Service in England, offers screening mammography once every three years to individuals between the age 50-70.<sup>(15)</sup>

### **3 Primary Objective**

To calculate the cancer detection rate in low-risk women who present for mammography at the breast imaging unit at HJH.

### **4 Secondary Objectives**

1. To assess the spectrum of disease found at mammography and sonography in low-risk women triaged and referred to the BIU.
2. Where biopsied, to correlate BI-RADS classification with the histology results.

### **5 Methodology**

#### **5.1 Research Paradigm**

This is a retrospective, observational, cross-sectional study – an internal audit.

#### **5.2 Sample**

Low-risk females who present for imaging at the BIU at HJH for the first six months during 2019.

##### **5.2.1 Inclusion Criteria**

1. Women triaged as low risk in the HJH breast clinic and subsequently referred to the HJH breast imaging unit.

##### **5.2.2 Exclusion Criteria**

1. A history of prior breast cancer.
2. Yellow and red coded patients.

### 5.2.3 Triage System

Patients are colour triaged according to an algorithm used in the HJH breast clinic. This is based on their history, examination and age of presentation as illustrated in Figure 1. High risk females were those who are colour coded as red, and intermediate risk females were those who are colour coded as yellow. Low risk females were classified as following: those over forty years of age, are asymptomatic, with bilateral mastalgia not related to an underlying medical condition and who require imaging for a non-surgical reason. These patients were classified as Green.

(Figure 1, Table 1).




Figure 1: The HJH Breast Clinic Triage Form.

Figure 1 describes the Triage Form currently in use at the HJH Breast Clinic and provides a flow diagram on how patients were assessed and their basic management plan.

Table 1: Triage criteria

| Colour       | Green                                                                                                                                                                                                                                                                                                | Yellow                                                                                                                                                                                                                                              | Red                                                                                                                                                        |
|--------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Criteria     | <p>Over 40 years:</p> <ul style="list-style-type: none"> <li>• Bilateral typical pain (no other medical cause)</li> <li>• Asymptomatic patients</li> <li>• Do not meet the criteria for yellow or red</li> <li>• Breast examination prior to initiation for hormonal replacement therapy.</li> </ul> | <p>Any age:</p> <ul style="list-style-type: none"> <li>• Unilateral pain</li> <li>• Nipple discharge- clear, bloody, or non-spontaneous</li> <li>• Palpable lymph node without any palpable mass</li> <li>• Soft mobile mass &lt;35years</li> </ul> | <p>Any age:</p> <ul style="list-style-type: none"> <li>• Any abscess, collection, or mass suspicious for cancer</li> <li>• Mass +/- lymph nodes</li> </ul> |
| Imaging Plan | <p>Screening MMG and ultrasound booked as a green case. Follow up at clinic in 3 months. If pain has resolved, to have a follow up MMG in 1 year. If not settled-become yellow</p>                                                                                                                   | <p>MMG and Ultrasound (if &gt;35 yr.) to be booked as a yellow case</p>                                                                                                                                                                             | <p>MMG and Ultrasound (if &gt;35 yr.) to be booked as a red case</p>                                                                                       |

Table 1 describes the HJH Breast Clinic Triage system, describing the criteria for green, yellow, and red patients and their imaging plan.

### 5.3 Time Period

Data were collected in a retrospective manner for the period of 6 months from 01/01/2019 to 30/06/2019.

### 5.4 Materials and Methods

All images were captured using the below machinery:

1. Mammogram: Hologic Linear Dimensions (tomosynthesis)
2. Stereotactic Biopsy: StereoBiopsyMulticare Platinum
3. Sonogram: Siemens Aplio 300 and Acuson NX3 Elite

Mammogram images were captured using the automatic exposure control setting. Ultrasonography images have been captured using a dedicated 14-megahertz handheld breast-probe.

### 5.5 Data Collection

Gathered data includes:

1. Age
2. Final BI-RADS risk assessment (Table 2)
3. BI-RADS breast density assessment
4. Mammographic imaging features
5. Ultrasound imaging features
6. Cases biopsied and their histology result

Table 2: BI-RADS Classification

| BI-RADS Category | Definition                      |
|------------------|---------------------------------|
| 0                | Incomplete imaging data         |
| 1                | Negative                        |
| 2                | Benign                          |
| 3                | Probably benign                 |
| 4                | Suspicious for malignancy       |
| 5                | Highly suggestive of malignancy |
| 6                | Known biopsy-proven malignancy  |

Table 2 describes the ACR BIRADS-Risk Assessment Classification.<sup>(16)</sup>

The following were calculated as per Breast Cancer Screening Consortium (BCSC) and American College of Radiology (ACR) calculation guidelines, as explained in Appendix A:<sup>(16)</sup>

1. Cancer Detection Rate
2. False Positive Rate
3. Specificity
4. Abnormal interpretation Rate

## 6 **Data Analysis and Statistics**

Statistical data was captured using Microsoft Excel. Calculations were done using the equations as per the ACR guidelines.<sup>(17)</sup>

## 7 **Ethics**

The study was approved by the Human Research Ethics Committee of the University of the Witwatersrand, approval number M201025 (appendix A).

## 8 Results

### 8.1 Figures and Tables




Figure 2: Age group versus patient count

Figure 2 totals the number of patients in each age-group.  
The most common age group was 60-69 years totalling 123.

Table 3: BIRADS Risk Assessment

| BIRADS Risk Assessment | Total |
|------------------------|-------|
| 1                      | 36    |
| 2                      | 326   |
| 3                      | 34    |
| 4                      | 2     |
| 5                      | 0     |

Table 3 gives the total of each BIRADS Risk assessment (1-4). BIRADS 0 and 6 were omitted.

BI-RADS 2 was the most common assessment totalling 326 (81.91%)




Figure 3: Patient Age versus BI-RADS Risk Assessment

Figure 3 describes the total count of the individual BIRADS Risk Assessment (1-4) in relation to each age group.

No patients were assessed as BIRADS 5.

Table 4: BIRADS Breast Density

| BIRADS Breast Density | Total |
|-----------------------|-------|
| A                     | 166   |
| B                     | 178   |
| C                     | 47    |
| D                     | 7     |

Table 4 gives a total count of the individual BIRADS Breast Density (A-D).

BIRADS Breast density B was the most common totalling 178 (44.72%).




Figure 4: Patient age versus BI-RADS breast density

Figure 4 describes the total count of the individual BIRADS Breast Density (A to D) in relation to each age group.

Table 5: Features of Mammographically Detected Masses

| <b>BIRADS Risk Assessment</b> | <b>1</b>  | <b>2</b>   | <b>3</b>  | <b>4</b> | <b>Grand Total</b> |
|-------------------------------|-----------|------------|-----------|----------|--------------------|
| 1. Multiple Masses            | 0         | 18         | 6         | 0        | 24                 |
| • <b>Bilateral Masses</b>     | <b>0</b>  | <b>14</b>  | <b>4</b>  | <b>0</b> | <b>18</b>          |
| ▪ Mass Shape                  |           |            |           |          |                    |
| ○ Oval                        | 0         | 8          | 1         | 0        | 9                  |
| ○ Round                       | 0         | 6          | 3         | 0        | 9                  |
| ○ Irregular                   | 0         | 0          | 0         | 0        | 0                  |
| • <b>Unilateral Masses</b>    | <b>0</b>  | <b>4</b>   | <b>2</b>  | <b>0</b> | <b>6</b>           |
| ▪ Mass Shape                  |           |            |           |          |                    |
| ○ Oval                        | 0         | 0          | 0         | 0        | 0                  |
| ○ Round                       | 0         | 4          | 2         | 0        | 6                  |
| ○ Irregular                   | 0         | 0          | 0         | 0        | 0                  |
| 2. No Masses                  | 36        | 266        | 20        | 1        | 323                |
| 3. Solitary Masses            | 0         | 42         | 8         | 1        | 51                 |
| • <b>Unilateral</b>           | <b>0</b>  | <b>42</b>  | <b>8</b>  | <b>1</b> | <b>51</b>          |
| ▪ Mass Shape                  |           |            |           |          |                    |
| ○ Oval                        | 0         | 17         | 2         | 0        | 19                 |
| ○ Round                       | 0         | 24         | 3         | 0        | 27                 |
| ○ Irregular                   |           | 1          | 3         | 1        | 5                  |
| <b>Grand Total</b>            | <b>36</b> | <b>326</b> | <b>34</b> | <b>2</b> | <b>398</b>         |

Table 5 documents the mammographic description of masses found, in relation to their overall BIRADS Risk Assessment (1-4). The mass descriptors are multiplicity and shape (oval, round or irregular).

Table 6: Features of Sonographically Detected Masses

|                                      | BIRADS Risk Assessment |            |           |          | Grand Total |
|--------------------------------------|------------------------|------------|-----------|----------|-------------|
|                                      | 1                      | 2          | 3         | 4        |             |
| 1. Mass                              | 1                      | 17         | 8         | 2        | 28          |
| • <b>Decreased Echo transmission</b> | 0                      | 2          | 1         | 0        | 3           |
| ▪ Mass Shape                         |                        |            |           |          |             |
| ○ Irregular                          | 0                      | 0          | 0         | 0        | 0           |
| ○ Oval                               | 0                      | 2          | 0         | 0        | 2           |
| ○ Round                              | 0                      | 0          | 1         | 0        | 1           |
| • <b>Increased Echo transmission</b> | 0                      | 2          | 1         | 0        | 3           |
| ▪ Mass Shape                         |                        |            |           |          |             |
| ○ Irregular                          | 0                      | 0          | 0         | 0        | 0           |
| ○ Oval                               | 0                      | 2          | 0         | 0        | 2           |
| ○ Round                              | 0                      | 0          | 1         | 0        | 1           |
| • <b>No Echo transmission</b>        | 1                      | 13         | 6         | 2        | 22          |
| ▪ Mass Shape                         |                        |            |           |          |             |
| ○ Irregular                          | 0                      | 0          | 1         | 2        | 3           |
| ○ Oval                               | 1                      | 11         | 2         | 0        | 14          |
| ○ Round                              | 0                      | 2          | 3         | 0        | 5           |
| 2. No Mass                           | 35                     | 309        | 26        | 0        | 370         |
| <b>Grand Total</b>                   | <b>36</b>              | <b>326</b> | <b>34</b> | <b>2</b> | <b>398</b>  |

Table 6 documents the ultrasound description of masses found in relation to their BIRADS Risk Assessment (1-4). The descriptors are-the presence or absence of a mass, their echo transmission (increase, decreased or non) and the mass shape (oval, round or irregular).

Table 7: Other Sonographic Findings

| BIRADS Risk Assessment |     | 1  | 2   | 3  | 4 | Total |
|------------------------|-----|----|-----|----|---|-------|
| USS Cysts              | Yes | 0  | 34  | 5  | 0 | 39    |
|                        | No  | 36 | 292 | 29 | 2 | 359   |
| USS collections        | Yes | 0  | 0   | 1  | 0 | 1     |
|                        | No  | 36 | 326 | 33 | 2 | 397   |
| USS Duct dilation      | Yes | 0  | 18  | 5  | 0 | 23    |
|                        | No  | 36 | 308 | 29 | 2 | 375   |

Table 7 documents the ultrasound findings (presence or absence of cysts, collections, duct dilation) in relation to the BIRADS Risk Assessment (1-4).

Table 8: Calcifications

|                     | Frequency  | Percentage  |
|---------------------|------------|-------------|
| 1. Calcification    | 42         | 10.55%      |
| • Non-suspicious    | 42         | 10.55%      |
| • Suspicious        | 0          | 0.00%       |
| 2. No calcification | 356        | 89.45%      |
| <b>Grand Total</b>  | <b>398</b> | <b>100%</b> |

Table 8 totals the number of patients found with calcifications on mammogram and the number of suspicious versus non-suspicious calcifications.

Table 9: Characteristics of Masses That Were Biopsied

| Imaging Characteristics        | Patient 1     | Patient 2   |
|--------------------------------|---------------|-------------|
| Age group                      | 40-49         | 30-39       |
| BI-RADS breast density         | B             | C           |
| BI-RADS risk assessment        | 4             | 4           |
| MMG: mass number               | Solitary      | None        |
| MMG: laterality of mass        | Unilateral    | NA          |
| MMG: mass borders              | Ill defined   | NA          |
| MMG: mass calcifications       | None          | NA          |
| USS: mass                      | Yes           | Yes         |
| USS: shape                     | Ill defined   | Ill defined |
| USS: echo through transmission | None          | None        |
| USS: axillary nodes            | Multiple      | None        |
| USS laterality of nodes        | Unilateral    | NA          |
| USS: duct dilation             | No            | No          |
| Histology                      | Not malignant | Malignant   |

Table 9 documents the individual characteristics of the BIRADS 4 masses that underwent biopsy.

Patient 2 had a malignant mass demonstrating Ductal Carcinoma.

Patient 1 had a non-malignant biopsy that did not demonstrate any malignant cells.

Table 10: Confusion Matrix

|                   |                           | Biopsy Results         |                          |
|-------------------|---------------------------|------------------------|--------------------------|
|                   |                           | Positive (malignant)   | Negative (non-malignant) |
| Screening Results | Positive (BIRADS 4)       | True Positive (TP): 1  | False Positive (FP): 1   |
|                   | Negative (BIRADS 1, 2, 3) | False Negative (FN): 0 | True Negative (TN): 396  |

Table 10 documents the confusion matrix in relation to screening results versus the biopsy results.

## 8.2 Calculations

The CDR was 2.51 per 1000. ACR recommended  $CDR \geq 2.5$ .<sup>(17)</sup>

$CDR = 1000 \times 1 / (1 + 1 + 0 + 396)$  or  $CDR = 1000 \times (1/398)$

$CDR = 1000 * TP / (TP + FP + FN + TN)$ .

The false positive rate (FPR) was 0.25%. North American False Positive Rate 10.2-14.4%.<sup>(18)</sup>

$FPR = 1 / (1 + 396)$ .

False Positive Rate (FPR) =  $FP / (FP + TN)$ .

The specificity was 99.75%. ACR reference range of 88.00-95.00%.<sup>(17)</sup>

$Specificity = 396 / (1 + 396)$ .

$Specificity = TN / (FP + TN)$ .

The abnormal interpretation rate was 0.50%. ACR (5.00-12.00%)<sup>(17)</sup> and the BCSC (11.6%).<sup>(19)</sup>

Abnormal interpretation rate =  $2/398$

Abnormal interpretation rate = Total positive exams / Total number of exams

## 9 **Discussion**

The CDR was 2.51 per 1000 people (1/398) which is within the ACR reference range.<sup>(17)</sup> The one patient who had a biopsy proven malignancy, fell below the age of 40 years and did not meet the age requirement for screening mammography. 30 out of 398 females (7.5%) were under the age of 40 and of this subset, 3 out of 30 (10%) were assessed as BIRADS 3 or higher, requiring short term follow up imaging. Screening mammography is not indicated below 40 years, except in high-risk individuals. Further research can assess as to whether patients are aware of a positive family history and/or genetic factors that may put them at a higher risk of breast cancer.




Figure 5: Pertinent findings versus total count

The most populous age group was 60-69 years (123 females, 30.90%) and the second most populous was 50-59 years (120 females, 30.15%). The BCSC reported the age group 50-59 year as their highest (30%) and 60-69 year old as the second highest (23.3%) patient count.<sup>(19)</sup> This discrepancy may be due to the limited period of the study and a late age of patient presentation for breast assessment. Further research into the age of initial presentation and a knowledge of primary prevention of breast cancer can be undertaken.

BIRADS Breast Density B was the most common tally (178, 44.72%). It remains the most common, however the overall percentage is low (44.47% versus 80%).<sup>(20)</sup> BIRADS Risk Assessment 2 represent 326 females (81.91%). This was not in keeping with other studies, in which BIRADS 1 was the most.<sup>(21, 22)</sup> These discrepancies may be due to a low patient number and a short study period.

The overwhelming majority of females were over the age of forty (92.46%), as recommended by both the RSSA and CANSA. This suggests that female of the correct age and risk profile are being referred as 'low risk' from the HJH breast clinic through to the BIU. Most of our patients fell in the age group 60-69 which was above international reference ranges.<sup>(19)</sup> Further research may explore the presenting complaint of females who present directly to either the HJH breast clinic or the BIU to ascertain the clinical stage at which females first seek breast screening practices.

6 out of 398 (1.5%) females were over the age of 80 years. From this subset, 1 patient (16.66%) was assessed as BIRADS 3. The ACR does not have an upper age limit, however the recommendation is that screening should take place if the patient's life-expectancy is estimated to be greater than 5-7 years.<sup>(16)</sup> This is not currently performed at HJH, and further studies could use modelling criteria to estimate the life-expectancy of low-risk females over the age of 75 years who underwent mammography at HJH BIU.

The low False Positive Rate, high specificity, and the abnormal interpretation rate in the study may in part be due to the lack of follow-up data. Follow up imaging results e.g., in females who were classified as BIRADS 3. Further study could explore the results in the subset of patients in which short term follow up imaging is advised.

In its current form, the study adds to the body of literature supporting the role of breast screening programs in detecting at-risk females. 36 out of 398 (9%) females were classified as BIRADS 3 or higher which require short term follow up. In all females >40 years (92.46%), follow-up imaging was recommended – this allows continued screening and promotes an increased awareness of breast health. The findings of this study support the ongoing use of the clinical triage

system in the HJH Breast Clinic. It may help to motivate for the use of a similar clinical triage system in a South African setting where there are insufficient resources to perform screening mammography.

## 10 **Study Limitations**

The study was conducted over a short duration (6months) due to time constraints and this resulted in a low number of patients (total 398). Further research over a prolonged period may be undertaken in future.

Due to the lack of formalised screening programs within the public health sector, a low-risk patient population was used.

A single hospital with a specified drainage area was used for this study. Further research may make use of multiple sites across different regions.

Data from short term follow up imaging was omitted. due to time constraints. Further research could analyse this data and assess the shortcoming in terms of sensitivity, recall rate, the ongoing false positive and false negative rate.

## 11 **Conclusion**

There is lack of data related to screening mammography within a Southern African context. This retrospective study assessed the CDR and spectrum of disease at the HJH BIU within Johannesburg, South Africa. The CDR was 2.51%, most females were between 60 to 69 years of age, BI-RADS A or B in density and BI-RADS 2. The above findings are within the recommended reference ranges by ACR and BCSC and will help to advocate for the use of similar triage systems in hospitals where resources do not allow for the implementation of breast screening programs.

1. Lin C-H, Yap YS, Lee K-H, Im S-A, Naito Y, Yeo W, et al. Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population. JNCI: Journal of the National Cancer Institute. 2019;111(12):1298-306.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018;68(6):394-424.
3. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. 2015;136(5):E359-86.
4. Organisation WH. Breast: Source Globocan 20202020. Available from: <https://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf>.
5. Adeloye D, Sowunmi OY, Jacobs W, David RA, Adeosun AA, Amuta AO, et al. Estimating the incidence of breast cancer in Africa: a systematic review and meta-analysis. Journal of Global Health. 2018;8(1).
6. Elvira S, Lactatia M, Lerato K, Mazvita S-M, Wenlong C, atasha AN. National Cancer Registry, South Africa. Ekurhuleni Population-Based Cancer Registry Annual 2018 Report. Johannesburg South Africa: National Health Laboratory Services; 2020.
7. Murphy A, RADSWIKI. Breast screening programmes: Radiopaedia; [Available from: Radiopaedia.org.
8. Drukteinis JS, Mooney BP, Flowers CI, Gatenby RA. Beyond Mammography: New Frontiers in Breast Cancer Screening. The American Journal of Medicine. 2013;126(6):472-9.
9. Lipschitz S. Screening mammography with special reference to guidelines in South Africa. 2018. 2018;22(2).
10. Herbst CM. Fact Sheet on Effective Radiation Received from Routine Mammography2017 [cited 2021 05/10/2021]. Available from: Fact-Sheet-Effective-Radiation-Received-from-Routine-Mammography-April-2017.pdf (cansa.org.za).
11. Brackstone M, Latosinsky S, Saettler E, George R. CJS debate: Is mammography useful in average-risk screening for breast cancer? Can J Surg. 2016;59(1):62-6.
12. Duffy SW, Tabár L, Yen AM-F, Dean PB, Smith RA, Jonsson H, et al. Mammography screening reduces rates of advanced and fatal breast cancers: Results in 549,091 women. Cancer. 2020;126(13):2971-9.
13. Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. Bmj. 2014;348:g366.
14. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151(10):716-26, w-236.
15. NHS. Breast Screening Programme, England 2019-2028 Jan 2021 06/05/2021.
16. Radiology ACo. ACR BI-RADS ATLAS-MAMMOGRAPHY: American College of Radiology; 2013. Available from: Mammography-Reporting (acr.org).
17. Radiology ACo. ACR BI-RADS® ATLAS — FOLLOW-UP AND OUTCOME MONITORING. II. THE BASIC CLINICALLY RELEVANT AUDIT 2013 [cited 2020 06/06/2020]. Available from: <https://www.acr.org/-/media/ACR/Files/RADS/BI-RADS/FUOM-Basic-Audit.pdf>.
18. Le MT, Mothersill CE, Seymour CB, McNeill FE. Is the false-positive rate in mammography in North America too high? The British journal of radiology. 2016;89(1065):20160045-.
19. BCSC. Benchmarks for Screening Sensitivity & Specificity 2017 [updated 2017; cited 2020 10/06/2020]. *"The Breast Cancer Surveillance Consortium and its data collection and sharing activities are funded by grants from the National Cancer Institute (P01CA154292, U54CA63303), Patient-Centered Outcomes Research Institute (PCS-1504-30370), and Agency for Health Research and Quality (R01 HS018366-01A1). Downloaded xx/xx/xxxx from the Breast Cancer Surveillance Consortium Web site -*

<http://www.bcsc-research.org/>. More information regarding the BCSC is available at: <http://bcsc-research.org/>. Available from: <https://www.bcsc-research.org/statistics/screening-performance-benchmarks/Benchmarks-sens-spec>.

20. Badan GM, Roveda Júnior D, Ferreira CAP, de Noronha Junior OA. Complete internal audit of a mammography service in a reference institution for breast imaging. *Radiologia brasileira*. 2014;47(2):74-8.

21. Winkel R, von Euler-Chelpin M, Nielsen M, Diao P, Nielsen MB, Uldall W, et al. Inter-observer agreement according to three methods of evaluating mammographic density and parenchymal pattern in a case control study: Impact on relative risk of breast cancer. *BMC Cancer*. 2015;15.

22. Magny S, Shikhman R, Keppke A. Breast Imaging Reporting and Data System. Treasure Island (FL): StatPearls Publishing; Updated 2021 Aug 31] [2021 Jan: Available from: <https://www.ncbi.nlm.nih.gov/books/NBK459169/>.

**Appendix A: Ethic Clearance Certificate**

UNIVERSITY OF THE  
WITWATERSRAND  
JOHANNESBURG



R49 Dr LR Naidu

**HUMAN RESEARCH ETHICS COMMITTEE (MEDICAL)  
CLEARANCE CERTIFICATE NO. M201025**

**NAME:** Dr LR Naidu  
(Principal Investigator)

**DEPARTMENT:** School of Clinical Medicine  
Department of Radiation Sciences  
Division of Diagnostic Radiology  
Medical School  
University


**PROJECT TITLE:** *An audit of clinically triaged women at low risk for breast cancer presenting to the Helen Joseph Hospital Mammography Unit, Johannesburg*

**DATE CONSIDERED:** 2020/10/30

**DECISION:** Approved unconditionally

**CONDITIONS:**

**SUPERVISOR:** Drs P Naidoo and G Rubin

**APPROVED BY:**   
Dr CB Penny, Chairperson, HREC (Medical)


**DATE OF APPROVAL:** 2021/01/26

This Clearance Certificate is valid for 5 years from the date of approval. An extension may be applied for.

**DECLARATION OF INVESTIGATORS**

To be completed in duplicate and **ONE COPY** returned to the Research Office secretariat on the 3rd floor, Phillip Tobias Building, Parktown, University of the Witwatersrand, Johannesburg.

I/we fully understand the conditions under which I am/we are authorized to carry out the above-mentioned research and I/we undertake to ensure compliance with these conditions. Should any departure be contemplated from the research protocol as approved, I/we undertake to submit details to the Committee. I agree to submit a yearly progress report. When a funder requires annual re-certification, the application date will be one year after the date when the study was initially reviewed. In this case, the study was initially reviewed in **October** and therefore reports and re-certification will be due in the month of **October** each year. Unreported changes to the study may invalidate the clearance given by the HREC (Medical).

  
Signature of Principal Investigator

31/01/2021.  
Date